K-Stem Cell, receives approval for the 2b- and 3-phase clinical trials on the stem cell treatment agent for degenerative arthritis
K-Stem Cell Co., Ltd. (CEO Kim Sang-gyo), a prominent enterprise specializing in adult stem cell technology in Korea, announced today that it has obtained approval for the 2-b and 3-phase clinical trial on JointStem, a stem cell treatment agent for degenerative arthritis, from the Ministry of Food and Drug Safety (MFDS) of Korea.
Read more
Most Commented